Advisory Board
Advisory Board (Scientific)
Dr. Argyrios Theofilopoulos M.D.

.Dr. Argyrios Theofilopoulos, M.D.  is a former chairman of the Department of Immunology and Microbial Science at the Scripps Research Institute in La Jolla, California. Dr. Theofilopoulos carries on his current work as a Full Professor at Scripps Dr. Theofilopoulos’ where his research centers on defining the molecular and genetic basis of autoimmune diseases, particularly systemic autoimmunity. Dr. Theofilopoulos has received several honorary doctoral degrees; he is a member of several scientific societies,  and an editor of a major text on Molecular Pathology of Autoimmune Diseases as well as Editor of the ongoing "Current Directions in Autoimmunity" series. He has published approximately 300 original papers and book chapters in medical and science books.

Advisory Board (Scientific)
Dr. Philip Kim

Dr. Phillip Kim received his Ph.D. ('00) and his postdoc in medical genetics at the Geffen School of Medicine (UCLA). He holds  MBA ('09) from the  Marshall Business School at USC. Dr. Kim has held senior and executive positions at  well-known companies such as  AGI, Prometheus Labs (acquired by Nestle  Health Sciences), and Pierian Biosciences.   He has published extensively in peer reviewed journals , written chapters in science books, and holds numerous international patents.  He is on the SAB of Batu Biologics (a cancer vaccine company) and CHIPSA (an oncology hospital)  Dr. Kim founded a pioneering immuno-oncology company, , Trutino Biosciences in 2017.  He is the founder of TulyNode,  an autologous immuno cell therapy oncology company. Dr. Kim is the  inventor and the licensor  to ONPH of its "patent-pending" immuno cell therapy in oncology space to ONPH.

Advisory Board (Scientific)
Dr. Henry Smith

Dr Smith has over 50 years experience in Healthcare. He is the co-founder of several biotech companies including NanoSmart Pharmaceuticals, Advanced Prenatal Therapeutics and Epinex Diagnostics. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds. England; and in 1966 published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. Throughout his career he has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer.   

Advisory Board (Scientific)

Vijay Mahant Ph.D.

Vijay Mahant received his MS., Ph.D.  and first post-doctorate from LUT (UK), He received his second post-doctorate from UT Health Science Center at Houston/MD Anderson, TX, USA).  Dr. Mahant is a scientist and an entrepreneur with more than 35 years of experience in immuno-and precision medicine (oncology, cardiology, pain management and psychiatric, etc).  He has held executive positions and he is founder/co-founder of diagnostic companies, He is currently the VP, Precision oncology, Batu Biologics.  Dr. Mahant has been involved in fund raisings, Initial Public Offerings (IPOs) and he has 30 issued patents and 10 patents pending; he has authored and/or co-authored publications in journals and science books. He is an associate editor of the "Journal of Translation Medicine" .  Dr. Mahant has managed intellectual property, including in and out licensing. He developed several FDA cleared products with multi-million dollars in revenues. Dr. Mahant is on the SAB/MAB of Batu Biologics (an oncology company ), CHIPSA Hospital (an oncology hospital) , Trutino Biosciences (an oncology company),  TulyNode (an autologous immune therapy company)  and  Immunicom (medical device company for oncology)

 

Advisory Board (Regulatory)
Dr. James Smith

More than 20 years of experience in the biotech industry. Specialized in the pre-clinical development and regulatory approval of numerous novel medical device and pharmaceutical products. Expertise in implementing highly effective corporate culture and quality management infrastructure compliant with US FDA and ISO regulations. Experienced in all aspects of product development.

President and CEO, Advanced Prenatal Therapeutics, Inc. (2013 – Present) 

Provides executive leadership and corporate and regulatory strategy for the company’s line of novel preeclampsia therapies. Oversees development of patented apheresis platform. 

President, NanoSmart Pharmaceuticals, Inc. (2010 – Present) 

Provides executive leadership and corporate and regulatory strategy for the company’s line of novel cancer drug therapies. Oversees development of patented immunoliposome drug delivery platform. 

Independent Regulatory Consultant (2006 – Present) 

Developed and implemented ISO, GMP, and GLP quality systems. Managed regulatory applications for various medical product manufacturers (510(k), PMA, IND/IDE, etc.). Supported product development efforts from R&D through commercialization. Supported clients with regulatory strategies, internal or agency audits, CAPA resolutions, efficient design/development activities, equipment/process validations, process-improvement activities, and regulatory/quality/product documentation.

Advisory Board (Legal)
Dimitri Theofilopoulos, Esq.

Mr. Dimitri Theofilopoulos co-founded Batu Biologics (a pioneering company in oncology) in December 2013, where he serves as a general counsel and  Chief Operating Officer. Mr. Theofilopoulos is a former (2010-2013)  Scripps Research Institute compliance attorney.   Prior to that, he practiced employment and healthcare law in Los Angeles, where he gained extensive litigation experience.  Mr. Theofilopoulos has a B. A degree in History from UCLA and a J.D from USC School of Law.  He is licensed to practice law in the State of California.

Advisory Board (Scientific)

Stefan Gruenwald, Ph.D./MD

Dr. Stefan Gruenwald is Founder and Managing Director of Genautica (http://www.genautica.com) a seed funding entity for high technology ventures. Genautica was the initial seed investor of Diagnomics (https://www.diagnomics.com) and participated in starting and funding the EONE-Diagnomics Genome Center (www.egdc.com) in Korea, an entity which went public for over 400 million USD on Kosdaq. Dr, Gruenwald has over 28 years experience in the Biotech Industry in San Diego, CA. He was the Chief Technology Officer at PharMingen (91-97) and the VP of R&D at Becton Dickinson (97-00). Dr. Gruenwald was also involved in several mergers and acquisitions in the $200+ MM range.

 

Academic degrees: MD / PhD (summa cum laude, Best-Thesis-Of-The-Year Award). Involved in technology scouting and evaluation for over 25 years.

Initiator and curator of a popular Science Newsletter ( https://www.scoop.it/topic/amazing-science ) with over 900,000 reads. Fluent in English and German. Studied Human Medicine, Biology and Physics at the Johann-Wolfgang-Goethe University in Frankfurt / Germany. Broad scientific knowledge in many disciplines, including Biotechnology and Nanotechnology.

 

Specialties: Biotechnology management, start-up company management, Fortune 100 company management, mergers and acquisitions, Venture Capital, Private Equity, Funds of Funds, International contacts, Russia, China. Nanotechnology Investment. 

1 Sansome Street, Suite 3500

San Francisco, CA 94104

info@oncology-pharma.com

 

415-869-1036

  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon
  • White Google+ Icon
Send Us a Message

© 2019 by Oncology Pharma Inc.